Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study

Authors :: Zweijpfenning, S.M.H.
Kops, S.E.P.
Boeree, M.J.
Kuipers, S.
Ingen, J. van
Hoefsloot, W.
Magis-Escurra, C.
Zweijpfenning, S.M.H.
Kops, S.E.P.
Boeree, M.J.
Kuipers, S.
Ingen, J. van
Hoefsloot, W.
Magis-Escurra, C.
Source :: ERJ Open Research; 2312-0541; 4; 7; 00466-2021; ~ERJ Open Research~~~~~2312-0541~4~7~~00466-2021
Publication Year :: 2021
Abstract: Contains fulltext : 242637.pdf (Publisher’s version ) (Open Access)<br />Addition of intravenous amikacin and clofazimine to recommended rifamycin-ethambutol-macrolide regimens yields favourable outcomes in severe M. avium complex pulmonary disease (MAC-PD). This five-drug regimen should be considered in select MAC-PD patients. https://bit.ly/30dxdRj.

Database :: OAIster
Journal :: ERJ Open Research; 2312-0541; 4; 7; 00466-2021; ~ERJ Open Research~~~~~2312-0541~4~7~~00466-2021
Publication Type :: Electronic Resource
Accession number :: edsoai.on1292464232
Document Type :: Electronic Resource

Tools